3 Hospital Pharma, Generic Formulations and Domestic Brands Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma
- October 21, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma: ROE of 11.7% to 18.7% and FY22 to FY26 revenue CAGR of 11.8% to 16.4%. Prices as of 20 Oct 2026.
Quick Answer
The three formulation pharma stocks to watch are Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 16.4%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Mankind Pharma has the fastest revenue growth at 16.4% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Formulation pharma stocks follow companies that make finished medicines for patients, whether sold through hospitals, pharmacies or export markets. Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma cover hospital-focused and specialty products, generic formulations and a large domestic brand portfolio.
This list covers three formulation pharma stocks with complete current figures: Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulation Pharma Stocks?
Formulation pharma stocks are listed companies that turn active ingredients into tablets, capsules, injectables and other finished doses. They earn from brand sales, hospital supply and generic exports, so their mix of markets shapes their growth and margins.
Formulation Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 1,766.6 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Strides Pharma Science | 1,029.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Mankind Pharma | 2,253.2 | 93,014 | 45.0 | 36.0 | 11.7 | 0.39 |
On valuation, Emcure Pharmaceuticals and Strides Pharma Science trade at a P/E below the industry P/E, while Mankind Pharma trades above it, which reflects the growth the market already expects. Readers comparing formulation pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Formulation Pharma Stocks Have a Strong Roadmap in India?
Formulation pharma stocks have a strong roadmap in India because domestic medicine use is rising and Indian makers continue to win share in regulated export markets.
- Domestic demand. Higher incomes and insurance cover increase medicine use across therapies.
- Export markets. Generic approvals in regulated markets open large, repeat demand.
- Hospital channel. Injectables and specialty products supplied to hospitals carry steady volumes.
Why Emcure Pharmaceuticals Features Among These Formulation Pharma Stocks
Among the formulation pharma stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Strides Pharma Science Features Among These Formulation Pharma Stocks
Among the generic pharma shares on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.
Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Mankind Pharma Features Among These Formulation Pharma Stocks
Among the three companies on this list, Mankind Pharma is one of India’s largest pharmaceutical companies by domestic sales, with a strong presence in chronic and acute therapies, consumer healthcare brands and a large field force.
The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0.
Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore.
Roadmap: The company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What to watch: Watch the market share in chronic therapies and the integration of acquired brands.
Emcure Pharmaceuticals vs Strides Pharma Science vs Mankind Pharma on Key Financials
The table below sets the three formulation pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Mankind Pharma | 7,978 | 14,636 | 16.4% | 1,938 | 13.2% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Mankind Pharma combines the largest FY26 revenue at Rs 14,636 crore with the fastest revenue growth, a 16.4% compound annual rate. A useful habit with formulation pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Mankind Pharma | 3,650 | 4,076 | 11.7% |
Key Risks to Check Before Investing in Formulation Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these formulation pharma stocks, the main points are: Long-term generic pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Price controls and generic competition can limit margins.
- Regulatory checks. Inspections at plants can delay launches.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter formulation pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Formulation Pharma Stocks
Formulation pharma stocks fit investors who prefer finished-product businesses with brand or distribution strength. Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma each have a defined route to market. Based on the 20 October 2026 close, Emcure Pharmaceuticals trades at Rs 1,766.6, Strides Pharma Science at Rs 1,029.3 and Mankind Pharma at Rs 2,253.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these formulation pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track formulation pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are formulation pharma stocks?
Ans. Formulation pharma stocks are listed companies that turn active ingredients into tablets, capsules, injectables and other finished doses. They earn from brand sales, hospital supply and generic exports, so their mix of markets shapes their growth and margins. This list looks at three of them, Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which formulation pharma stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, Strides Pharma Science and Mankind Pharma. Based on the 20 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,766.6, Strides Pharma Science at Rs 1,029.3 and Mankind Pharma at Rs 2,253.2. Their return on equity ranges from 11.7% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.8% to 16.4%.
Why do formulation pharma stocks have a strong future roadmap in India?
Ans. Formulation pharma stocks have a strong roadmap in India because domestic medicine use is rising and Indian makers continue to win share in regulated export markets. The main drivers are as follows. Domestic demand. Higher incomes and insurance cover increase medicine use across therapies. Export markets. Generic approvals in regulated markets open large, repeat demand. Hospital channel. Injectables and specialty products supplied to hospitals carry steady volumes. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Mankind Pharma performed financially?
Ans. Revenue rose from Rs 7,978 crore in FY22 to Rs 14,636 crore in FY26, a compound annual growth rate of 16.4%. Net profit grew from Rs 1,453 crore in FY22 to Rs 1,938 crore in FY26, which works out to a compound annual growth rate of 7.5%. In the June 2026 quarter, revenue grew 11.7% year on year to Rs 4,076 crore, while net profit rose 29.1% to Rs 574 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.39 and a market capitalisation of Rs 93,014 crore. The stock trades at a P/E of 45.0, above the industry P/E of 36.0. Looking ahead, the company combines a wide field force with a portfolio of leading brands, and has added scale through the acquisition of Bharat Serums and Vaccines. New launches in chronic therapies and a growing consumer healthcare business broaden the base.
What risks should investors check before buying formulation pharma stocks?
Ans. Investors should check a few risks before buying formulation pharma stocks. Pricing pressure. Price controls and generic competition can limit margins. Regulatory checks. Inspections at plants can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of formulation pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
